市場調査レポート
商品コード
1462271
TEPEZZAの市場規模、予測、市場考察(2032年)TEPEZZA Market Size, Forecast, and Market Insight - 2032 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
TEPEZZAの市場規模、予測、市場考察(2032年) |
出版日: 受注後更新
発行: DelveInsight
ページ情報: 英文 30 Pages
納期: 2~10営業日
|
インスリン様成長因子1受容体阻害薬(IGF-1R)であるテプロツムマブは、チャイニーズハムスター卵巣(CHO-DG44)細胞で産生される完全ヒトIgG1モノクローナル抗体で、分子量は約148KDです。
テプロツムマブの代謝は完全には明らかにされていませんが、タンパク質分解による代謝が予測されます。注射用TEPEZZAは、無菌、防腐剤フリー、白色か灰色の凍結乾燥粉末として供給され、静脈注射に使用されます。各単回投与バイアルには、500mgのテプロツムマブ、L-ヒスチジン(7.45mg)、L-ヒスチジン塩酸塩一水和物(31.8mg)、ポリソルベート20(1mg)とトレハロース二水和物(946mg)が含まれます。10mLの滅菌注射用水(USP)で再構成した後、最終濃度は47.6mg/mLで、pHは5.5です。
当レポートでは、主要7市場(米国・ドイツ・フランス・イタリア・スペイン・英国・日本)におけるバセドウ病眼症向けTEPEZZAについて調査分析し、作用機序、用法と用量、研究開発活動についての考察、収益の予測などを提供しています。
"TEPEZZA Market Size, Forecast, and Market Insight - 2032" report provides comprehensive insights about TEPEZZA for Graves' Ophthalmopathy in the seven major markets. A detailed picture of the TEPEZZA for Graves' Ophthalmopathy in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2019 -2032 is provided in this report along with a detailed description of the TEPEZZA for Graves' Ophthalmopathy. The report provides insights about mechanism of action, dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of future market assessments inclusive of the TEPEZZA market forecast analysis for Graves' Ophthalmopathy in the 7MM, SWOT, analysts' views, comprehensive overview of market competitors, and brief about other emerging therapies in Graves' Ophthalmopathy.
Teprotumumab, an insulin-like growth factor-1 receptor inhibitor (IGF-1R), is a fully human IgG1 monoclonal antibody produced in Chinese hamster ovary (CHO-DG44) cells with a molecular weight of approximately 148 KD.
The metabolism of teprotumumab has not been fully characterized; however, it is expected to undergo metabolism via proteolysis. TEPEZZA for injection is supplied as a sterile, preservative-free, and white to off-white, lyophilized powder for IV infusions. Each single-dose vial contains 500 mg of teprotumumab, L-histidine (7.45 mg), L-histidine hydrochloride monohydrate (31.8 mg), polysorbate 20 (1 mg), and trehalose dihydrate (946 mg). After reconstitution with 10 mL of sterile water for injection, USP, the final concentration is 47.6 mg/mL with a pH of 5.5.
The recommended dose of TEPEZZA is an IV infusion of 10 mg/kg for the initial dose, followed by an IV infusion of 20 mg/kg every 3 weeks for seven additional infusions.
Teprotumumab's mechanism of action in patients with Graves' Ophthalmopathy has not been fully characterized. It binds to IGF-1R and blocks its activation and signaling.
The report provides insights into:
The report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight's team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
TEPEZZA Analytical Perspective by DelveInsight
This report provides a detailed market assessment of TEPEZZA for Graves' Ophthalmopathy in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2024 to 2032.
The report provides the clinical trials information of TEPEZZA for Graves' Ophthalmopathy covering trial interventions, trial conditions, trial status, start and completion dates.